ARHGAP23

Summary

ARHGAP23 (Rho GTPase activating protein 23, HGNC:29293) is a protein-coding gene on chromosome 17q12, encoding Rho GTPase-activating protein 23 (Q9P227). GTPase activator for the Rho-type GTPases by converting them to an inactive GDP-bound state.

The RHO (see ARHA; MIM 165390) family of small GTPases are involved in signal transduction through transmembrane receptors, and they are inactive in the GDP-bound form and active in the GTP-bound form. GTPase-activating proteins, such as ARHGAP23, inactivate RHO family proteins by stimulating their hydrolysis of GTP (Katoh and Katoh, 2004 [PubMed 15254754]).

Source: NCBI Gene 57636 — RefSeq curated summary.

At a glance

• GWAS associations: 9
• Clinical variants (ClinVar): 313 total
• Phenotypes (HPO): 1
• MANE Select transcript: NM_001199417

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29293
Approved symbol	ARHGAP23
Name	Rho GTPase activating protein 23
Location	17q12
Locus type	gene with protein product
Status	Approved
Aliases	KIAA1501
Ensembl gene	ENSG00000275832
Ensembl biotype	protein_coding
OMIM	610590
Entrez	57636

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 8 protein_coding, 2 retained_intron, 2 nonsense_mediated_decay

ENST00000614693, ENST00000616767, ENST00000616909, ENST00000617798, ENST00000618325, ENST00000618942, ENST00000619156, ENST00000620325, ENST00000620329, ENST00000620417, ENST00000622683, ENST00000633445

RefSeq mRNA: 1 — MANE Select: NM_001199417 NM_001199417

CCDS: CCDS56027

Canonical transcript exons

ENST00000610551 — 0 exons

Expression profiles

Bgee: expression breadth ubiquitous, 134 present calls, max score 97.35.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 29.6965 / max 739.2196, expressed in 1472 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
160485	15.2917	1382
160489	5.9869	1153
160488	5.6180	1146
160483	1.9308	346
160487	0.6105	450
160484	0.1507	73
160490	0.0604	17
160493	0.0474	6

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sural nerve	UBERON:0015488	97.35	gold quality
corpus callosum	UBERON:0002336	97.28	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	96.82	gold quality
substantia nigra	UBERON:0002038	95.08	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	94.68	gold quality
skin of leg	UBERON:0001511	94.46	gold quality
right hemisphere of cerebellum	UBERON:0014890	94.45	gold quality
cortical plate	UBERON:0005343	94.42	gold quality
Ammon’s horn	UBERON:0001954	94.28	gold quality
cerebellum	UBERON:0002037	94.26	gold quality
cerebellar cortex	UBERON:0002129	94.22	gold quality
cerebellar hemisphere	UBERON:0002245	94.20	gold quality
zone of skin	UBERON:0000014	94.18	gold quality
esophagus mucosa	UBERON:0002469	94.06	gold quality
temporal lobe	UBERON:0001871	93.87	gold quality
amygdala	UBERON:0001876	93.85	gold quality
skin of abdomen	UBERON:0001416	93.71	gold quality
stromal cell of endometrium	CL:0002255	93.49	gold quality
primary visual cortex	UBERON:0002436	93.14	gold quality
putamen	UBERON:0001874	92.90	gold quality
right frontal lobe	UBERON:0002810	92.90	gold quality
anterior cingulate cortex	UBERON:0009835	92.72	gold quality
esophagus	UBERON:0001043	92.67	gold quality
hypothalamus	UBERON:0001898	92.57	gold quality
cerebral cortex	UBERON:0000956	92.50	gold quality
frontal cortex	UBERON:0001870	92.47	gold quality
placenta	UBERON:0001987	92.40	gold quality
Brodmann (1909) area 9	UBERON:0013540	92.38	gold quality
popliteal artery	UBERON:0002250	92.32	gold quality
tibial artery	UBERON:0007610	92.30	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.18

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

81 targeting ARHGAP23, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-5193	100.00	67.26	1744
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-6870-5P	99.99	68.55	2115
HSA-MIR-4723-5P	99.97	68.70	2034
HSA-MIR-5698	99.97	68.49	2029
HSA-MIR-7111-5P	99.97	68.48	2062
HSA-MIR-6825-5P	99.96	69.81	3431
HSA-MIR-4725-3P	99.96	69.53	2520
HSA-MIR-6780B-5P	99.96	69.60	2562
HSA-MIR-128-3P	99.95	71.17	2484
HSA-MIR-216A-3P	99.95	71.19	2505
HSA-MIR-101-3P	99.94	75.03	2230
HSA-MIR-144-3P	99.94	73.98	2698
HSA-MIR-338-5P	99.92	72.34	2951
HSA-MIR-374A-5P	99.90	71.34	2923
HSA-MIR-374B-5P	99.90	69.98	2734
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-4302	99.89	67.94	1187
HSA-MIR-4271	99.88	68.32	2244
HSA-MIR-3681-3P	99.88	70.46	2254
HSA-MIR-3941	99.86	70.54	2735
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-3150A-3P	99.76	64.44	1640
HSA-MIR-6763-5P	99.76	64.68	1767
HSA-MIR-6794-5P	99.76	66.38	1048
HSA-MIR-3680-3P	99.75	72.51	3095
HSA-MIR-149-3P	99.72	68.22	3963

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	arhgap23a	ENSDARG00000052950
mus_musculus	Arhgap23	ENSMUSG00000049807
rattus_norvegicus	Arhgap23	ENSRNOG00000022771
drosophila_melanogaster	RhoGAP19D	FBGN0031118
caenorhabditis_elegans		WBGENE00015418

Paralogs (1): ARHGAP21 (ENSG00000107863)

Protein

Protein identifiers

Rho GTPase-activating protein 23 — Q9P227 (reviewed: Q9P227)

Alternative names: Rho-type GTPase-activating protein 23

All UniProt accessions (9): Q9P227, A0A087WTU4, A0A087WXU2, A0A087WZ73, A0A087WZZ2, A0A087X0Z0, A0A087X1W6, A0A9L9PXQ2, A0A9L9PXS4

UniProt curated annotations — full annotation on UniProt →

Function. GTPase activator for the Rho-type GTPases by converting them to an inactive GDP-bound state.

Tissue specificity. Expressed in placenta, prostate, hippocampus and brain medulla. Also expressed in brain tumor, salivary gland tumor, head and neck tumor.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9P227-1	1	yes
Q9P227-2	2

RefSeq proteins (1): NP_001186346* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000198	RhoGAP_dom	Domain
IPR001478	PDZ	Domain
IPR001849	PH_domain	Domain
IPR008936	Rho_GTPase_activation_prot	Homologous_superfamily
IPR011993	PH-like_dom_sf	Homologous_superfamily
IPR036034	PDZ_sf	Homologous_superfamily
IPR041489	PDZ_6	Domain
IPR041681	PH_9	Domain

Pfam: PF00620, PF15410, PF17820

UniProt features (31 total): modified residue 11, region of interest 8, compositionally biased region 4, domain 3, splice variant 2, chain 1, site 1, cross-link 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9P227-F1	49.82	0.16

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 942 (arginine finger; crucial for gtp hydrolysis by stabilizing the transition state)

Post-translational modifications (12): 361, 372, 423, 517, 583, 611, 623, 656, 659, 662, 677, 854

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-8980692	RHOA GTPase cycle
R-HSA-9013149	RAC1 GTPase cycle

MSigDB gene sets: 104 (showing top): MIDORIKAWA_AMPLIFIED_IN_LIVER_CANCER, GOBP_REGULATION_OF_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION, CHARAFE_BREAST_CANCER_LUMINAL_VS_BASAL_DN, CERVERA_SDHB_TARGETS_1_UP, GOBP_SMALL_GTPASE_MEDIATED_SIGNAL_TRANSDUCTION, BOCHKIS_FOXA2_TARGETS, GOMF_ENZYME_ACTIVATOR_ACTIVITY, GOMF_NUCLEOSIDE_TRIPHOSPHATASE_REGULATOR_ACTIVITY, GOMF_ENZYME_REGULATOR_ACTIVITY, LIU_PROSTATE_CANCER_DN, BAKKER_FOXO3_TARGETS_DN, GOBERT_OLIGODENDROCYTE_DIFFERENTIATION_DN, ZWANG_CLASS_1_TRANSIENTLY_INDUCED_BY_EGF, REACTOME_RHO_GTPASE_CYCLE, GSE13522_WT_VS_IFNAR_KO_SKING_T_CRUZI_Y_STRAIN_INF_DN

GO Biological Process (2): signal transduction (GO:0007165), regulation of small GTPase mediated signal transduction (GO:0051056)

GO Molecular Function (2): GTPase activator activity (GO:0005096), protein binding (GO:0005515)

GO Cellular Component (2): cytosol (GO:0005829), extracellular exosome (GO:0070062)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
RHO GTPase cycle	2

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
small GTPase-mediated signal transduction	1
regulation of intracellular signal transduction	1
GTPase activity	1
enzyme activator activity	1
GTPase regulator activity	1
binding	1
cytoplasm	1
cellular anatomical structure	1
extracellular vesicle	1

Protein interactions and networks

STRING

694 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ARHGAP23	CCDC85C	A6NKD9	605
ARHGAP23	PRICKLE1	Q96MT3	592
ARHGAP23	CCDC85A	Q96PX6	576
ARHGAP23	ZNF541	Q9H0D2	528
ARHGAP23	CCDC51	Q96ER9	508
ARHGAP23	RASA1	P20936	497
ARHGAP23	SRCIN1	Q9C0H9	489
ARHGAP23	ARHGAP21	Q5T5U3	470
ARHGAP23	PLEK2	Q9NYT0	468
ARHGAP23	PLEK	P08567	454
ARHGAP23	CCDC85B	Q15834	421
ARHGAP23	GPR137C	Q8N3F9	397
ARHGAP23	TCP11L2	Q8N4U5	387
ARHGAP23	SOCS4	Q8WXH5	379
ARHGAP23	SOCS7	O14512	378

IntAct

43 interactions, top by confidence:

A	B	Type	Score
CSNK2B	NMT2	psi-mi:“MI:0914”(association)	0.660
ASF1B	HAT1	psi-mi:“MI:0914”(association)	0.640
PNMA2	CCDC85C	psi-mi:“MI:0914”(association)	0.530
ZNRD2	CCDC85C	psi-mi:“MI:0914”(association)	0.530
YWHAB	PLEKHG3	psi-mi:“MI:0914”(association)	0.480
YWHAQ	PLEKHG3	psi-mi:“MI:0914”(association)	0.480
ABCC4	ARHGAP23	psi-mi:“MI:0407”(direct interaction)	0.440
ARHGEF16	ARHGAP23	psi-mi:“MI:0407”(direct interaction)	0.440
ASIC3	ARHGAP23	psi-mi:“MI:0407”(direct interaction)	0.440
ATP2B4	ARHGAP23	psi-mi:“MI:0407”(direct interaction)	0.440
CYSLTR2	ARHGAP23	psi-mi:“MI:0407”(direct interaction)	0.440
DGKK	ARHGAP23	psi-mi:“MI:0407”(direct interaction)	0.440
ARHGAP23	DGKZ	psi-mi:“MI:0407”(direct interaction)	0.440
DOCK4	ARHGAP23	psi-mi:“MI:0407”(direct interaction)	0.440
FRMPD4	ARHGAP23	psi-mi:“MI:0407”(direct interaction)	0.440
FZD7	ARHGAP23	psi-mi:“MI:0407”(direct interaction)	0.440
ARHGAP23	TAMALIN	psi-mi:“MI:0407”(direct interaction)	0.440
E6	ARHGAP23	psi-mi:“MI:0407”(direct interaction)	0.440
ORF putative E6	ARHGAP23	psi-mi:“MI:0407”(direct interaction)	0.440
KCNA5	ARHGAP23	psi-mi:“MI:0407”(direct interaction)	0.440
KIR3DL3	ARHGAP23	psi-mi:“MI:0407”(direct interaction)	0.440
MAP2K2	ARHGAP23	psi-mi:“MI:0407”(direct interaction)	0.440
PBK	ARHGAP23	psi-mi:“MI:0407”(direct interaction)	0.440
RALBP1	ARHGAP23	psi-mi:“MI:0407”(direct interaction)	0.440
SLC15A5	ARHGAP23	psi-mi:“MI:0407”(direct interaction)	0.440
SLCO1C1	ARHGAP23	psi-mi:“MI:0407”(direct interaction)	0.440
TJP2	ARHGAP23	psi-mi:“MI:0407”(direct interaction)	0.440
NEK4	E2F8	psi-mi:“MI:0914”(association)	0.350

BioGRID (69): ARHGAP23 (Affinity Capture-MS), ARHGAP23 (Proximity Label-MS), ARHGAP23 (Affinity Capture-MS), ARHGAP23 (Affinity Capture-MS), ARHGAP23 (Affinity Capture-RNA), ARHGAP23 (Proximity Label-MS), ARHGAP23 (Affinity Capture-MS), ARHGAP23 (FRET), ARHGAP23 (FRET), ARHGAP23 (Affinity Capture-MS), AZGP1 (Affinity Capture-MS), CTNNA1 (Affinity Capture-MS), FASTKD1 (Affinity Capture-MS), GSPT1 (Affinity Capture-MS), HP1BP3 (Affinity Capture-MS)

ESM2 similar proteins: A1L1I3, A5PKW4, O08919, O70405, O75385, O75420, O75553, P16554, P42128, P49757, P53814, P85037, P97318, P98081, Q04637, Q2LC84, Q3UCQ1, Q4KMP7, Q5DTT2, Q5I1X5, Q5RBR0, Q5VZ18, Q69ZH9, Q69ZI1, Q7TN02, Q7Z6J0, Q80VC9, Q80XI3, Q80Z38, Q86V15, Q8BGT6, Q8BHL3, Q8BSD5, Q8C120, Q8CI12, Q8IY33, Q8K4J6, Q8N3F8, Q8TEH3, Q8TEJ3

Diamond homologs: A0A0G2JTR4, A1A4S6, A2AB59, A2RUV4, A4IF90, A4II46, A6QNS3, A6X8Z5, A7KAX9, A7YY57, A8WRJ2, D3ZFJ3, E7EZG2, E7F3F0, F1LXF1, O14559, O94466, P11274, P15882, P30337, P34288, P38339, P46941, P52757, P55194, P81128, P97393, Q03070, Q08DP6, Q10164, Q12979, Q13017, Q15311, Q17QN0, Q20498, Q2M1Z3, Q3TBD2, Q3UIA2, Q52LW3, Q53QZ3

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
ARHGAP23	“down-regulates activity”	RHOA	“gtpase-activating protein”
ARHGAP23	“down-regulates activity”	RAC1	“gtpase-activating protein”

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 49 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Apoptosis	5	25.4×	2e-04
RHOG GTPase cycle	5	22.5×	2e-04
Programmed Cell Death	5	22.2×	2e-04
CDC42 GTPase cycle	6	13.1×	2e-04
RAC1 GTPase cycle	5	9.2×	3e-03
Signaling by Rho GTPases	6	6.2×	4e-03
Signaling by Rho GTPases, Miro GTPases and RHOBTB3	6	6.1×	5e-03

GO biological processes:

GO term	Partners	Fold	FDR
regulation of small GTPase mediated signal transduction	5	16.4×	5e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

313 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	288
Likely benign	7
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

4545 predictions. Top by Δscore:

Variant	Effect	Δscore
17:38458261:AAGG:A	donor_loss	1.0000
17:38458262:AGG:A	donor_loss	1.0000
17:38458264:GT:G	donor_loss	1.0000
17:38458265:T:G	donor_loss	1.0000
17:38463112:CCCCA:C	acceptor_loss	1.0000
17:38463113:CCCA:C	acceptor_loss	1.0000
17:38463114:CCAG:C	acceptor_loss	1.0000
17:38463115:CAG:C	acceptor_loss	1.0000
17:38463116:A:AG	acceptor_gain	1.0000
17:38463117:G:GG	acceptor_gain	1.0000
17:38463117:GGA:G	acceptor_gain	1.0000
17:38463194:TAGGT:T	donor_loss	1.0000
17:38463195:AGGT:A	donor_loss	1.0000
17:38463196:GGT:G	donor_loss	1.0000
17:38463197:G:C	donor_loss	1.0000
17:38463197:G:GG	donor_gain	1.0000
17:38463325:TAGTG:T	acceptor_loss	1.0000
17:38463326:A:AG	acceptor_gain	1.0000
17:38463326:A:C	acceptor_loss	1.0000
17:38463326:AGT:A	acceptor_gain	1.0000
17:38463327:G:GT	acceptor_gain	1.0000
17:38463327:GT:G	acceptor_gain	1.0000
17:38463327:GTG:G	acceptor_gain	1.0000
17:38463327:GTGAT:G	acceptor_gain	1.0000
17:38466160:T:TA	acceptor_gain	1.0000
17:38467330:TGGT:T	donor_loss	1.0000
17:38467331:GGT:G	donor_loss	1.0000
17:38467332:G:GG	donor_gain	1.0000
17:38467332:G:T	donor_loss	1.0000
17:38467333:T:G	donor_loss	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000003840 (17:38446317 G>A), RS1000035807 (17:38428991 C>T), RS1000119538 (17:38485790 C>T), RS1000131812 (17:38480941 T>C), RS1000176129 (17:38419556 G>A), RS1000228825 (17:38512560 A>C), RS1000242894 (17:38491803 A>G), RS1000300631 (17:38440212 T>C), RS1000328513 (17:38470241 C>T), RS1000395896 (17:38507750 T>G), RS1000418974 (17:38424901 T>C), RS1000433289 (17:38480625 C>A,T), RS1000449980 (17:38423163 C>T), RS1000481215 (17:38437979 A>AG), RS1000508338 (17:38466788 G>A)

Disease associations

OMIM: gene MIM:610590 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): microcephaly (MONDO:0001149)

Orphanet (0):

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0000252	Microcephaly

GWAS associations

9 associations (top):

Study	Trait	p-value
GCST001941_16	Ovarian cancer	8.000000e-10
GCST004613_62	Sum neutrophil eosinophil counts	6.000000e-10
GCST004614_58	Granulocyte count	7.000000e-10
GCST004626_141	Myeloid white cell count	2.000000e-10
GCST012485_14	Cerebral amyloid angiopathy x sex interaction in Alzheimer’s disease	1.000000e-05
GCST90002393_519	Monocyte count	1.000000e-09
GCST90002398_269	Neutrophil count	1.000000e-11
GCST90002404_161	Red cell distribution width	1.000000e-12
GCST90002407_130	White blood cell count	1.000000e-13

EFO canonical traits (6, from GWAS)

EFO ID	Trait name
EFO:0004833	neutrophil count
EFO:0004842	eosinophil count
EFO:0007987	granulocyte count
EFO:0008343	sex interaction measurement
EFO:0005091	monocyte count
EFO:0009188	Red cell distribution width

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D008831	Microcephaly	C05.660.207.620; C10.500.507.400.500; C16.131.621.207.620; C16.131.666.507.400.500

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

55 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Particulate Matter	decreases expression, increases abundance, increases expression, affects cotreatment	4
Air Pollutants	affects cotreatment, decreases expression, increases abundance, increases expression	3
Aflatoxin B1	decreases methylation, increases expression, affects methylation	3
(+)-JQ1 compound	decreases expression	2
Arsenic	affects methylation, affects cotreatment, decreases expression, increases abundance	2
Benzo(a)pyrene	affects methylation	2
Phenylmercuric Acetate	increases expression, affects cotreatment	2
aristolochic acid I	increases expression	1
FR900359	affects phosphorylation	1
TAK-243	increases sumoylation	1
methylmercuric chloride	increases expression	1
alpha-pinene	affects cotreatment, decreases expression, increases abundance	1
pirinixic acid	affects binding, decreases expression, increases activity	1
bisphenol A	affects cotreatment, increases methylation, affects methylation	1
testosterone undecanoate	affects cotreatment, increases expression	1
cinnamaldehyde	increases expression	1
beta-lapachone	decreases expression	1
sodium arsenite	affects cotreatment, decreases expression, increases abundance	1
manganese chloride	affects cotreatment, decreases expression, increases abundance	1
coumarin	increases phosphorylation	1
muconaldehyde	decreases expression	1
methacrylaldehyde	affects cotreatment, decreases expression, increases abundance	1
S-(1,2-dichlorovinyl)cysteine	increases expression, affects cotreatment, decreases expression, affects response to substance	1
beta-methylcholine	affects expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
erucylphospho-N,N,N-trimethylpropylammonium	decreases expression	1
abrine	increases expression	1
dorsomorphin	increases expression, affects cotreatment	1
MT19c compound	decreases expression	1
2,3,5-trichloro-6-phenyl-(1,4)benzoquinone	decreases expression	1

Clinical trials (associated diseases)

17 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT05518188	PHASE1/PHASE2	RECRUITING	Melpida: Recombinant Adeno-associated Virus (serotype 9) Encoding a Codon Optimized Human AP4M1 Transgene (hAP4M1opt)
NCT00001639	Not specified	COMPLETED	Evaluation of Patients With Unresolved Chromosome Abnormalities
NCT01151462	Not specified	WITHDRAWN	Postnatal HCMV Infection in Very Preterm Infants. Implications, Morbidity, Growth and Neurodevelopmental Outcomes.
NCT01565005	Not specified	COMPLETED	Microcephaly Genetic Deficiency in Neural Progenitors
NCT02510170	Not specified	COMPLETED	Fetal and Maternal Head Circumference During Pregnancy in Israeli Population
NCT02741882	Not specified	COMPLETED	Zika and Microcephaly: Case-control Study
NCT02943304	Not specified	COMPLETED	Neurodevelopment Outcome of Newborns Exposed to Zika Virus (ZIKV) in Utero
NCT03255369	Not specified	UNKNOWN	Vertical Exposure to Zika Virus and Its Consequences for Child Neurodevelopment (ZIKVIRUSIFF)
NCT03325946	Not specified	RECRUITING	The FBRI VTC Neuromotor Research Clinic
NCT03330600	Not specified	COMPLETED	Efficacy of Aquatic Physiotherapy in Children With Microcephaly by Zika Virus Congenital Syndrome
NCT03548779	Not specified	COMPLETED	North Carolina Genomic Evaluation by Next-generation Exome Sequencing, 2
NCT03651687	Not specified	COMPLETED	Guangzhou Surveillance and Clinical Study in Microcephaly (GSCSM)
NCT03922594	Not specified	TERMINATED	Surveillance of Zika-related Microcephaly in Sub-Saharan Africa and Asia
NCT04816175	Not specified	COMPLETED	Intensive Therapy for Children With Microcephaly, Hyperkinetic Movements, or Global Developmental Delay
NCT05322980	Not specified	COMPLETED	Summary of Infants Weighing 500 Grams or Less
NCT06019182	Not specified	RECRUITING	MEHMO Natural History and Biomarkers
NCT06566066	Not specified	RECRUITING	Register for Patients With Thyroid Hormone Resistance.